TL;DR - Fourteen major mass tort cases are actively tracked on this site as of May 2026, spanning pharmaceuticals, medical devices, environmental contamination, and social media. - Three cases have reached significant settlements: Roundup ($11B+), Philips CPAP ($1.1B personal injury), and Camp Lejeune (administrative track, $700M+ paid). - The social media addiction MDL entered its first bellwether trial in January 2026, with TikTok and Snap settling confidentially before proceedings concluded. - Six cases are in the discovery and Daubert phase, with bellwether trials expected in 2026 and 2027. - Three cases (Depo-Provera, Bard PowerPort, and GLP-1/Ozempic) are in early MDL stages with no trials scheduled.
Mass tort cases move through a predictable sequence of stages: MDL formation, discovery, bellwether trials, settlement negotiations, and claims administration. But every case moves at a different pace, and the difference between a case in early discovery and one with a $10 billion settlement matters enormously to the people whose claims are pending.
This page gives a plain-language status snapshot of every major mass tort case tracked on this site, as of May 2026. Cases are grouped by litigation phase so readers can quickly find where a specific case stands. Each entry links to the full case page, which carries detailed eligibility information, settlement figures, science background, and litigation history.
For an explanation of how the MDL process works from start to finish, see the nine-stage guide on this site. For an explanation of how bellwether trials drive settlement value, see the bellwether trial guide.
What do the phase labels mean?
Each case in this guide carries one of four phase labels: Settled, Trials active, Discovery/Daubert, or Early stage. These reflect where the litigation stands in the MDL process as of the date of this article.
Settled means a global resolution has been reached covering most or all remaining claims. Individual claimants may still be in the claims administration process receiving payments, but the litigation itself is substantially concluded.
Trials active means bellwether trials are underway or have recently concluded. Verdicts from these cases are shaping settlement negotiations for the remaining plaintiff group.
Discovery/Daubert means the litigation has moved past initial consolidation and document exchange. Parties are preparing or arguing Daubert motions, which determine whether expert scientific testimony will be admitted at trial. Bellwether trial dates are typically set or anticipated at this stage.
Early stage means the MDL is newly formed or still being established. Discovery has not concluded and no trial schedule has been set.
Which mass tort cases have already settled?
Three cases have achieved global or near-global resolution as of May 2026: Roundup, Philips CPAP, and Camp Lejeune. Claimants in those cases may still be in the claims administration process awaiting individual payments.
Roundup (Glyphosate) | Settled
Defendant: Bayer AG (Monsanto) Alleged injuries: Non-Hodgkin's lymphoma and other cancers linked to glyphosate herbicide exposure MDL: Multiple federal and state proceedings; primary resolution through a global settlement program
Bayer committed more than $11 billion to resolve approximately 100,000 Roundup claims. Three consecutive plaintiff bellwether wins between 2018 and 2019, with jury awards ranging from $80 million to $2 billion before appeal reductions, established the scale of potential liability and drove negotiations. Phase 1 per-case settlements were reported in the range of $100,000 to $160,000. A proposed class settlement of $7.25 billion for future claimants received preliminary court approval in March 2026.
Philips CPAP Recall | Settled
Defendant: Koninklijke Philips N.V. / Philips Respironics Alleged injuries: Lung cancer, kidney cancer, liver cancer, bladder cancer, and respiratory injuries from degraded polyurethane foam in recalled CPAP, BiPAP, and ventilator devices MDL: No. 3014, Western District of Pennsylvania, Judge Joy Flowers Conti
Philips reached a $1.1 billion settlement structured in tiers by injury severity and device usage duration. A separate $479 million economic loss settlement covers device replacement costs and other non-injury damages. A $1.1 billion Department of Justice and FTC consent decree addressed regulatory violations. The June 2021 recall affected approximately 5.5 million US devices. Personal injury claims for plaintiffs not covered by the settlement or who opted out continue in the MDL.
Camp Lejeune Water Contamination | Administrative track
Defendant: US Government Alleged injuries: Kidney cancer, bladder cancer, leukemia, non-Hodgkin's lymphoma, Parkinson's disease, and other conditions linked to contaminated water at the North Carolina military base between 1953 and 1987 Process: PACT Act administrative claims, not a standard MDL
Camp Lejeune claims are processed through the Department of Justice rather than through bellwether trials. The Elective Option program pays tiered amounts ranging from approximately $100,000 to over $550,000 per claim, based on condition severity and exposure documentation. The DOJ had disbursed more than $700 million in settlements as of March 2026, with 649 new settlements approved in that month alone totaling $175 million. Over 600,000 administrative claims have been filed. The Congressional Budget Office estimated total liability at approximately $21 billion.
Which mass tort cases are in active trials right now?
Three cases are currently in the bellwether trial phase, with jury verdicts being used to establish settlement values for the broader plaintiff group: social media addiction, NEC baby formula, and J&J talcum powder.
Social Media Youth Addiction | Trials active
Defendants: Meta Platforms (Facebook/Instagram), TikTok (ByteDance), Snap Inc., Google (YouTube), X Corp. Alleged injuries: Depression, anxiety, eating disorders, self-harm, suicidal ideation, and other mental health harms in children and adolescents MDL: No. 3047, Northern District of California; California state coordination: JCCP 5255, Los Angeles Superior Court
The social media MDL entered its first bellwether trial in January 2026. Jury selection began January 27, 2026 in Los Angeles Superior Court in the case KGM v. Meta and YouTube, with trial proceedings commencing February 10, 2026. TikTok and Snap reached confidential settlements before the trial concluded. As of March 2026, plaintiffs had presented their case-in-chief, including testimony from Meta CEO Mark Zuckerberg. More than 10,000 individual cases and approximately 800 school district cases are pending across federal and state proceedings.
NEC Baby Formula | Trials active
Defendants: Abbott Laboratories (Similac), Mead Johnson Nutrition/Reckitt Benckiser (Enfamil) Alleged injuries: Necrotizing enterocolitis (NEC), infant death, short bowel syndrome, sepsis, and developmental delays in premature infants fed cow's milk-based formula MDL: No. 3026, Northern District of Illinois, Judge Rebecca R. Pallmeyer
The NEC formula MDL has produced mixed bellwether results. In March 2024, a jury awarded $60 million against Mead Johnson in the first bellwether trial. In October 2025, the judge granted Abbott summary judgment in a third bellwether case, a significant defense win that may affect how plaintiffs' claims against Abbott proceed. The mixed record complicates settlement negotiations and means per-case values remain contested.
Johnson and Johnson Talcum Powder | Trials active
Defendant: Johnson and Johnson Alleged injuries: Ovarian cancer and mesothelioma linked to talc-based products including Baby Powder MDL: Federal MDL proceeding toward bellwether trials; multiple state court cases also active
talcum powder MDL has no global settlement in place. Three attempts to resolve claims through a subsidiary bankruptcy filing were rejected, most recently on March 31, 2025. A Philadelphia jury returned a $1.56 billion verdict against J&J in February 2026. Earlier trial results include a 2018 St. Louis jury award of $4.69 billion to 22 plaintiffs, later reduced to $2.12 billion on appeal. With bankruptcy unavailable, the MDL is proceeding toward federal bellwether trials that will shape settlement negotiations.
Which mass tort cases are in discovery or Daubert preparation?
Four cases have moved past initial consolidation into active discovery, with Daubert motions scheduled or pending: hair relaxer, AFFF firefighting foam, hernia mesh, and IVC filters. Bellwether trial dates in these cases are anticipated in 2026 and 2027.
Hair Relaxer Cancer | Discovery/Daubert
Defendants: L'Oréal USA, Revlon, Namaste Laboratories, Strength of Nature, Dabur International, Godrej Consumer Products Alleged injuries: Uterine cancer, endometrial cancer, ovarian cancer, uterine fibroids, and endometriosis linked to chemical hair relaxer products MDL: No. 3060, Northern District of Illinois, Judge Mary M. Rowland
The hair relaxer litigation has grown to more than 11,000 filed cases, with approximately 247 new cases added monthly as of March 2026. Daubert motions on expert scientific testimony were due April 1, 2026, a critical juncture that will determine whether plaintiffs' causation theory survives to trial. Initial bellwether trials are targeted for 2027. No settlements have been reached.
AFFF Firefighting Foam (PFAS) | Discovery/Daubert
Defendants: 3M Company, DuPont/Chemours, and other foam manufacturers Alleged injuries: Bladder cancer, kidney cancer, testicular cancer, thyroid disease, and other conditions linked to per- and polyfluoroalkyl substances (PFAS) in firefighting foam MDL: District of South Carolina; multiple settlement funds for water utility claims
Water utility settlements have reached substantial scale: 3M agreed to pay $10.3 billion over 13 years for public water system contamination, and DuPont entities committed $1.185 billion. Approximately 8,000 individual personal injury cases remain active in the MDL as of early 2026. Per-case values for personal injury claimants depend on bellwether trial outcomes not yet concluded.
Hernia Mesh | Discovery/Daubert
Defendants: C.R. Bard/Becton Dickinson, Atrium Medical, Covidien/Medtronic, Ethicon/Johnson and Johnson Alleged injuries: Mesh migration, organ adhesion, chronic pain, infection, bowel obstruction, and revision surgery complications MDLs: Bard MDL No. 2846 (S.D. Ohio, ~24,000 pending cases); Atrium MDL (D. New Hampshire); Covidien MDL (D. Massachusetts)
The hernia mesh litigation spans multiple MDLs against different manufacturers. The Bard MDL, the largest with approximately 24,000 pending cases, has bellwether trials expected in 2026. Individual trial verdicts have ranged from several million to over $50 million. The Ethicon Physiomesh litigation has been largely resolved through confidential settlement programs. Thousands of individual cases across all defendants have settled, though specific amounts remain undisclosed.
IVC Filters | Discovery/Daubert
Defendants: C.R. Bard/Becton Dickinson, Cook Medical Alleged injuries: Filter fracture, migration, organ perforation, pulmonary embolism, cardiac tamponade, and death from retrievable inferior vena cava filters MDL: Bard MDL No. 2641, District of Arizona; Cook cases in Southern District of Indiana
The IVC filter litigation follows two tracks. Bard/Becton Dickinson has resolved thousands of claims through confidential settlement programs since MDL establishment in 2015, with individual amounts varying by injury severity. Cook Medical has not reached a global settlement, and cases continue to be litigated individually in the Southern District of Indiana.
Early-stage mass tort cases
These MDLs are newly formed or still being established. No discovery has concluded and no bellwether trial dates have been set.
Depo-Provera | Early stage
Defendant: Pfizer Inc. and Greenstone LLC Alleged injuries: Intracranial meningioma (brain tumors), requiring surgery in many cases, linked to prolonged use of the injectable contraceptive MDL: Middle District of Florida (Jacksonville), established January 2025, Judge Marcia Morales Howard
The Depo-Provera litigation formed in January 2025 with 78 initial cases, a number growing rapidly. Discovery commenced March 27, 2025. Five pilot cases were selected in February 2025 to advance through the litigation process. Expert witness deadlines run through early 2026, with first trials expected in late 2026 or early 2027. No settlements have been reached.
Bard PowerPort Catheter | Early stage
Defendant: C.R. Bard / Becton Dickinson and subsidiary Navilyst Medical Alleged injuries: Catheter fracture, migration, vascular injury, infection, deep vein thrombosis, cardiac tamponade, pulmonary embolism, and death from implantable port catheters MDL: Pending in District of Arizona; MDL formation proceedings before the JPML
The Bard PowerPort litigation is in its earliest stage, with 208 new cases filed in a single recent month, representing 15.5% growth in filings. Discovery is underway but no Daubert motions or bellwether trial schedule has been set. No settlements have been reached.
GLP-1 / Ozempic / Wegovy | Early stage
Defendants: Novo Nordisk A/S (Ozempic, Wegovy, Saxenda), Eli Lilly and Company (Mounjaro, Zepbound, Trulicity) Alleged injuries: Gastroparesis (stomach paralysis), bowel obstruction, ileus, aspiration pneumonia, pancreatitis, and gallbladder disease MDL: No. 3094, Eastern District of Pennsylvania, established 2024
The GLP-1 litigation filed its 244-page Master Complaint in November 2024. Defendants filed motions to dismiss in January 2025. With 1,600+ cases pending and monthly status conferences underway, the litigation remains in preliminary motion practice. No Daubert rulings, no discovery completion, and no bellwether schedule has been set. This case carries significant scientific and legal uncertainty.
Zantac: state court litigation after federal dismissal
Zantac (Ranitidine) | State courts
Defendants: Sanofi, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, and generic manufacturers Alleged injuries: Bladder, stomach, liver, esophageal, pancreatic, and colorectal cancers linked to NDMA contamination in ranitidine products Federal MDL: No. 2924, Southern District of Florida; effectively dismissed December 2022
The Zantac litigation took an unusual path. Federal MDL Judge Robin Rosenberg excluded plaintiffs' general causation experts in December 2022, finding their methodologies unreliable under the Daubert standard. Without admissible expert testimony, the federal MDL was effectively dismissed. State court litigation continues, primarily in Delaware Superior Court, where judges have reached different conclusions on expert admissibility. No global settlement has been reached. The case illustrates how a Daubert ruling can reshape an entire litigation, and why the upcoming Daubert decisions in cases like hair relaxer and Depo-Provera are closely watched.
Resolved cases (kept for reference)
Two cases previously tracked on this site have been substantially resolved.
3M Combat Arms Earplugs: The largest single-defendant mass tort MDL in US history, with more than 300,000 claims, reached a global resolution in 2023. 3M committed $6 billion to settle claims from military veterans who alleged the dual-ended earplugs were defective and caused hearing loss.
Paraquat (Parkinson's Disease): Claims against Syngenta and Chevron alleging that the herbicide paraquat caused Parkinson's disease were resolved following Daubert rulings that limited plaintiffs' causation evidence. Individual settlements were reached in many cases.
How can you follow developments in your case?
Each case summary above links to a dedicated page on this site with full litigation history, eligibility criteria, settlement details, and regular status updates.
For the cases most likely to see significant developments in the coming months, watch for: the outcome of the social media addiction bellwether trial in Los Angeles; Daubert rulings in the hair relaxer MDL (April 2026 motion deadline); bellwether trial scheduling in the Bard hernia mesh MDL; and the motion to dismiss decision in the GLP-1/Ozempic litigation.
A bellwether trial result or a Daubert ruling can change the trajectory of a mass tort case quickly. The litigation status page for each case on this site is updated as significant developments occur.
The information on mass-torts.com is for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by using this website. Laws vary by state and jurisdiction. For advice about your specific situation, consult a licensed attorney in your jurisdiction. mass-torts.com is not a law firm and does not provide legal representation.